DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Glufosfamide
Glufosfamide
Wien, 28
Draft COMP Agenda 16-18 January 2018
Pharmaceutical Appendix to the Tariff Schedule 2
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Orphan Drug Designation List
(12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub
Chemotherapy and Radiotherapy for Advanced Pancreatic Cancer (Review)
Adis R&D Insight
(12) (19) Standard Patent Australian Patent Office
(12) United States Patent (10) Patent No.: US 9,676,746 B2 Decrescenzo Et Al
Stembook 2018.Pdf
2018 Medicines in Development for Cancer
Developments in Carbohydrate-Based Cancer Therapeutics
A Guide to Ongoing Clinical Trials in Pancreatic Cancer1
Current Status and Dilemma of Second-Line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
Providing for Duty-Free Treatment for Specified Pharmaceutical Active
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Prognostic Impact of Combined Fludarabine, Treosulfan and Mitoxantrone Resistance Profile in Childhood Acute Myeloid Leukemia
Top View
Orphan Drug Designation List
July Through September 2013
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
(12) United States Patent (10) Patent No.: US 8,987.491 B2 Collery Et Al
Draft COMP Agenda 6-8 November 2018
Journal Pre-Proof
COMP Agenda of the 11-13 July 2017 Meeting
2020 Medicines in Development ꟷ Cancer
Customs Tariff - Schedule Xxi - 1
Open Label Phase II Study on Glufosfamide Administered As a 60-Minute Infusion Every 3 Weeks in Recurrent Glioblastoma Multiforme
COMP Agenda of the 10-12 November 2015 Meeting
Pancreatic Cancer in 2014
Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
Curriculum Vitae
(12) Patent Application Publication (10) Pub. No.: US 2010/0226943 A1 Brennan Et Al
Oncology Drugs in the Pipeline
Harmonized Tariff Schedule of the United States (2006) (Rev
(12) United States Patent (10) Patent No.: US 9,642,796 B2 Packhaeuser Et Al
Oncology Drugs in the Pipeline
Customs Tariff - Schedule
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
Formula Ϊ O O W O 2011/163330 AI Llll II II 11III II I I III II II II II III II I II
Medicines & Vaccines in Development for Cancer
Best Practices for the Treatment of Metastatic Pancreatic Adenocarcinoma: the Therapeutic Landscape in 2017
Oncology Drugs in the Pipeline
Randomized Trials in Exocrine Pancreatic Cancer
Ex Vivo Responsiveness of Head and Neck Squamous Cell Carcinoma to Glufosfamide, a Novel Alkylating Agent
The Chemomodulatory Effects of Glufosfamide on Docetaxel Cytotoxicity in Prostate Cancer Cells
Clinical Pharmacology of Ifosfamide and Metabolites
(12) United States Patent (10) Patent No.: US 7,001,888 B2 Tidmarsh Et Al
Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016